

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

NATL ASSN OF CHAIN DRUG STORES

2. Address:

413 N LEE ST., ALEXANDRIA, VA 22314

3. Principal place of business (if different from line 2):

Country: City: State/Zip(or Country): HOLLAND

4. Contact Name: R. JAMES HUBER

Telephone: 703-549-3001

E-mail (optional): jhuber@nacds.org

Senate ID #: 26672-12

House ID #:

7. Client Name: Self

TYPE OF REPORT

8. Year 2006 Midyear (January 1 - June 30): **OR** Year End (July 1 - December 31):

9. Check if this filing amends a previously filed version of this report:

10. Check if this is a Termination Report: => Termination Date: 11. No Lobbying Activity:

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000:

\$10,000 or more: => Income (nearest \$20,000): _____

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000:

\$10,000 or more: => Expenses (nearest \$20,000): 460,000.00

14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

Method A. Reporting amounts using LDA definitions only

Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: PHA (one per page)

16. Specific lobbying issues:

1. H.R. 4241, House Deficit Reduction Act of 2005 2. S. 1932, Senate Deficit Reduction Act of 2005 3. H.R. 3199, USA Patriot Act Reauthorization 4. S. 1716, Emergency Health Care Relief Act of 2005 5. H.R. 4297, the Tax Relief Extension Reconciliation Act 6. H.R. 3010, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2006 7. S. 544, the Patient Safety and Quality Improvement Act of 2005 8. H.R. 3205, the Patient Safety and Quality Improvement Act of 2005 9. H.R. 1132, the National All Schedules Prescription Electronic Reporting Act of 2005 10. S. 518, the National All Schedules Prescription Electronic Reporting Act of 2005 11. S. 1392, the Federal Trade Commission Reauthorization Act of 2005 12. S. 334, the Pharmaceutical Market Access and Drug Safety Act 13. H.R. 700, the Pharmaceutical Market Access and Drug Safety Act of 2005 14. S. 309, the Pharmaceutical Market Access Act 15. H.R. 328, the Pharmaceutical Market Access Act 16. S.3, the Protecting America in the War on Terror Act of 2005 17. H.R. 3010, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2006 18. H.R. 1808, the Safe Online Drug Act of 2005 19. S. 399, the Ryan Haight Internet Pharmacy Consumer Protection Act of 2005 20. H.R. 840, the Ryan Haight Internet Pharmacy Consumer Protection Act of 2005 21. S. 14, the Fair Wage, Competition, and Investment Act of 2005 22. S. 534, the Health Efficient, Accessible, Low-Cost, Timely Healthcare Act of 2005 23. H.R. 5, the Health Efficient, Accessible, Low-Cost, Timely Healthcare Act of 2005 24. H.R. 1669, the Pharmacy Benefit Manager Transparency Act of 2005 25. H.R. 1671, the Community Pharmacy Fairness Act of 2005 26. S. 103, the Combat Meth Act of 2005 27. H.R. 314, the Combat Meth Act of 2005 28. S. 102, the Exile Meth Act 29. H.R. 313, the Exile Meth Act 30. H.R. 3889, Meth Epidemic Elimination Act 31. H.R. 1446, the Methamphetamine Abuse Prevention Act of 2005 32. H.R. 1055, the Comprehensive Methamphetamine Response Act 33. H.R. 1056, the Methamphetamine Precursor Control Act of 2005 34. H.R. 1378, the Ephedrine Alkaloids Regulation Act of 2005 35. H.R. 2829, the Office of National Drug Control Policy Reauthorization Act of 2005 36. H.R. 3617, the Medicare Value-Based Purchasing for Physicians' Services Act of 2005 37. S. 1356, the Medicare Value Purchasing Act of 2005 38. S. 1408, the Identity Theft Protection Act 39. S. 1332, the Personal Data Privacy and Security Act of 2005 40. S. 930, the Food and Drug Administration Safety Act of 2005 41. H.R. 1652, the Access to Legal Pharmaceuticals Act 42. S. 809, the Access to Legal Pharmaceuticals Act 43. H.R. 1539, a bill to amend the Public Health Service Act with respect to the responsibilities of a pharmacist employed by the pharmacy refuses to fill a valid prescription for a drug 44. S. 338, the Bipartisan Commission on Medicaid Act of 2005 45. H.R. 985, the Bipartisan Commission on Medicaid Act of 2005 46. S. Con.Res.18, Budget FY2006 Appropriations resolution 47. H. Con.Res.95, 18, Budget FY2006 Appropriations resolution 48. S. 1262, the Health Technology to Enhance Quality Act of 2005 49. S.3678, the Pandemic and All-Hazards Preparedness Act 50. S.2564, the Biodefense and Pandemic Vaccine and Drug Development Act of 2006 51. H.R. 5533, the Biodefense and Pandemic Vaccine and Drug Development Act 52. H.R. 5262, Tax Free Savings Act of 2006 53. S. 3546, the Dietary Supplement and Nonprescription Drug Consumer Protection Act 54. H.R. 4157, the Health Information Technology Promotion Act of 2005 55. S. 2766, the National Defense Authorization Act for Fiscal Year 2007 56. S.2810, the Medicare Late Enrollment Assistance Act of 2006 57. H.R.5399, the Medicare Drug Benefit Enrollment Fairness Act of 2006 58. H.R. 5182, the Fair and Speedy Treatment (FAST) of Medicare Prescription Drug Claims Act of 2006 59. S. 2563, the Pharmacist Access and Recognition in Medicare (PhARM) Act of 2006 60. S. 2664, the Pharmacy Access Improvement (PhAlm) Act of 2006 61. H.R. 4769, the Prescription Drug Elimination Act of 2006 62. S. 2300, the Lower Prices With Increased Competition and Efficient Development of Drugs Act (the Lower Priced Drugs Act) 63. H.R. 5166 | The Independent Pharmacy Protection Act of 2006 64. S. 2181, the Medicare State Reimbursement Act 65. S. 2183, the Requiring Emergency Pharmaceutical Access for Individual Relief (REPAIR) Act 66. H.R. 4297, the Tax Relief Extension Reconciliation Act 67. H.R. 5384, the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2007 68. H.R.5441, the Department of Homeland Security Appropriations Act, 2007 69. S. 2020, Tax Relief Act of 2005

17. House(s) of Congress and Federal agencies contacted:

Administration on Aging
Centers For Medicare and Medicaid Services (CMS)
Consumer Product Safety Commission
Defense, Dept of (DDO)
Drug Enforcement Administration (DEA)
Food & Drug Administration (FDA)
HOUSE OF REPRESENTATIVES
Health & Human Services, Dept of (HHS)
Office of Personnel Management (OPM)
SENATE
White House Office

18. Name of each individual who acted as a lobbyist in this issue area:

Registrant Name: NATL ASSN OF CHAIN DRUG STORES Client Name: Self

Name: CHOE, YONG

Covered Official Position (if applicable): N/A

Name: COSTER, JOHN M.

Covered Official Position (if applicable): N/A

Name: FRY, KATHERINE

Covered Official Position (if applicable): N/A

Name: HANNAN, BOB

Covered Official Position (if applicable): N/A

Name: KHANI, JULIE A.

Covered Official Position (if applicable): N/A

Name: POWELL, PAUL

Covered Official Position (if applicable): N/A

Name: VERSTANDIG, LEE

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Jul 28, 2006

Printed Name and Title: R. JAMES HUBER - SENIOR VICE PRESIDENT, FINANCE

Information Update Page:

Complete **ONLY** where registration information has changed.

LOBBYIST UPDATE

23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client

Name: FOGT, LAURA C.

Name: FULLER, CRAIG

Name: HARTWELL, ROBERT

Name: KELLY, PAUL T.

Name: KOCOT, S. LAWRENCE

Name: LAMBERT, DAVID F. III

Name: LINK, JAMES E.

ISSUE UPDATE

24. General lobbying issues previously reported that NO LONGER pertain

AFFILIATED ORGANIZATIONS

25. Add the following organization(s)

26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization

Signature: ON FILE Date: Jul 28, 2006

Printed Name and Title: R. JAMES HUBER - Senior Vice President, Finance